drugset / Trial / NCT06521255
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom
Timeline
- Start
- 2024-05-07
- Primary completion
- 2028-09
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Tafasitamab | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |